Coronavirus

Universal Life Selects Sapiens to Modernise its Core Systems

Sapiens' solution will accelerate Universal Life's growth and efficiency ROCHELLE PARK, N.J., April 15, 2025 /PRNewswire/ -- Sapiens International Corporation (NASDAQ:…

13 minutes ago

Glass House Brands Announces Hemp Research and Development Agreement with the University of California, Berkeley

LONG BEACH, Calif. and TORONTO, April 09, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company")…

6 days ago

Services PMI® at 50.8%; March 2025 Services ISM® Report On Business®

Business Activity Index at 55.9%; New Orders Index at 50.4%; Employment Index at 46.2%; Supplier Deliveries Index at 50.6% TEMPE,…

2 weeks ago

Aligos Therapeutics Presents Positive Data at APASL 2025

SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical…

3 weeks ago

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses

These candidates, previously shown to be active in vitro against respiratory syncytial virus (RSV) and human parainfluenza virus 3 (hPIV3),…

3 weeks ago

Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc.…

1 month ago

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

- Topline data expected as early as mid-2025 - SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart,…

1 month ago

Services PMI® at 53.5%; February 2025 Services ISM® Report On Business®

Business Activity Index at 54.4%; New Orders Index at 52.2%; Employment Index at 53.9%; Supplier Deliveries Index at 53.4% TEMPE, Ariz., March…

1 month ago

Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company…

1 month ago

Aligos Therapeutics Announces $105 Million Private Placement Financing

Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical study Funding expected to extend cash runway into…

2 months ago